Abstract
Combined traditional Chinese medicine directed penetration therapy can improve the anxiety symptoms of patients with schizophrenia and has a safe profile.
Introduction
Anxiety is a frequent and debilitating comorbid condition in schizophrenia, affecting approximately 65% of patients. While antipsychotic medications effectively manage core psychotic symptoms, the treatment of accompanying anxiety often necessitates the addition of antidepressants or benzodiazepines. However, these pharmacological additions frequently introduce a "side-effect trap": second-generation antidepressants can cause gastrointestinal distress and sexual dysfunction, while benzodiazepines carry risks of sedation and dependency. Consequently, there is a significant clinical need for safer, non-invasive alternatives that can improve patient quality of life without increasing the pharmacological burden.
Methodology
This study employed a randomized controlled trial (RCT) involving 80 patients at the Shanghai Mental Health Center. Participants were divided into a treatment group and a control group. Both groups received a standard dose of Olanzapine (10–25 mg).
The treatment group additionally received transdermal drug delivery therapy. This intervention utilized the DS-MF2B specialized instrument, which employs bioelectricity to facilitate the penetration of volatile oil from Polygonum multiflorum Thunb—a TCM herb traditionally used to "calm the mind"—through the skin. The therapy was targeted at two specific acupuncture points: ST36 (Zusanli) and SP6 (Sanyinjiao), known for their roles in regulating the nervous system.
Key Results and Clinical Insights
The primary outcome measure was the Hamilton Anxiety Scale (HAMA). After six weeks of treatment, the following results were observed:
- Significant Anxiety Reduction: HAMA scores in the treatment group decreased significantly compared to the control group (p < 0.001), dropping from an average of 17.80 to 15.38.
- Selective Efficacy: Interestingly, the therapy specifically improved anxiety symptoms but did not significantly impact core psychotic symptoms (PANSS) or depressive symptoms (HAMD-17). This indicates that the transdermal TCM approach serves as a specialized adjunctive tool for anxiety management.
- Correlation with Disease Duration and Baseline Severity: Statistical analysis revealed that patients with a shorter duration of schizophrenia experienced greater improvements. Furthermore, a positive correlation (R = 0.483, p = 0.002) was found between higher baseline anxiety levels and the degree of clinical improvement.
Safety and Tolerability
The transdermal route successfully bypassed the liver and gastrointestinal tract. The study reported no significant difference in adverse effects between the treatment and control groups, as measured by the Treatment Emergent Symptom Scale (TESS). This confirms the therapy's favorable safety profile, avoiding the common side effects associated with oral anxiolytics.
Discussion and Limitations
While promising, the authors note that this is a preliminary exploratory study. Limitations include the relatively small sample size (n=80) and the absence of a sham-controlled group, which makes it difficult to entirely rule out a placebo effect. Future research should incorporate objective biological markers—such as serotonin or inflammatory cytokine levels—to further elucidate the underlying mechanisms of this integrated therapeutic approach.
In conclusion, this study demonstrates that combining modern transdermal delivery technology with traditional herbal medicine offers a viable and safe strategy for managing comorbid anxiety in patients with schizophrenia.
Summary updated